121 related articles for article (PubMed ID: 36849281)
1. Peripheral facial palsy post SARS-CoV-2 vaccine: A regional pharmacovigilance cases series.
Chamboux M; Simon C; Beau-Salinas F; Maurier A; Agier MS; Thillard EM; Largeau B; Jonville-Bera AP
Therapie; 2023; 78(6):705-709. PubMed ID: 36849281
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
3. Global and regional burden of vaccine-associated facial paralysis, 1967-2023: Findings from the WHO international pharmacovigilance database.
Jeong YD; Lee K; Lee S; Park J; Kim HJ; Lee J; Kang J; Jacob L; Smith L; Rahmati M; López Sánchez GF; Dragioti E; Son Y; Kim S; Yeo SG; Lee H; Yon DK
J Med Virol; 2024 Jun; 96(6):e29682. PubMed ID: 38783823
[TBL] [Abstract][Full Text] [Related]
4. Capillary leak syndrome following COVID-19 vaccination: Data from the European pharmacovigilance database Eudravigilance.
Ruggiero R; Balzano N; Di Napoli R; Mascolo A; Berrino PM; Rafaniello C; Sportiello L; Rossi F; Capuano A
Front Immunol; 2022; 13():956825. PubMed ID: 36177033
[TBL] [Abstract][Full Text] [Related]
5. Potential Association Between COVID-19 Vaccination and Facial Palsy: Three Cases With Neuroimaging Findings.
Hamid R; Korkmazer B; Kochan Kizilkilic E; Arman GM; Ozogul M; Kargın OA; Arslan S; Kizilkilic O
Ear Nose Throat J; 2024 Jun; 103(1_suppl):110S-114S. PubMed ID: 35855585
[TBL] [Abstract][Full Text] [Related]
6. Facial nerve palsy following the administration of COVID-19 mRNA vaccines: analysis of a self-reporting database.
Sato K; Mano T; Niimi Y; Toda T; Iwata A; Iwatsubo T
Int J Infect Dis; 2021 Oct; 111():310-312. PubMed ID: 34492394
[TBL] [Abstract][Full Text] [Related]
7. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
8. Vaccines and Bell's palsy: A narrative review.
Bertin B; Grenet G; Pizzoglio-Billaudaz V; Lepelley M; Atzenhoffer M; Vial T
Therapie; 2023; 78(3):279-292. PubMed ID: 36038397
[TBL] [Abstract][Full Text] [Related]
9. Safety Signal Generation for Sudden Sensorineural Hearing Loss Following Messenger RNA COVID-19 Vaccination: Postmarketing Surveillance Using the French Pharmacovigilance Spontaneous Reporting Database.
Thai-Van H; Valnet-Rabier MB; Anciaux M; Lambert A; Maurier A; Cottin J; Pietri T; Destère A; Damin-Pernik M; Perrouin F; Bagheri H
JMIR Public Health Surveill; 2023 Jul; 9():e45263. PubMed ID: 37071555
[TBL] [Abstract][Full Text] [Related]
10. [Peripheral facial palsy following COVID-19 vaccination: a case report].
Kharoubi S
Pan Afr Med J; 2021; 40():244. PubMed ID: 35233264
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
16. Observed-over-Expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting.
van der Boom MDX; van Eekeren R; van Hunsel FPAM
Pharmacoepidemiol Drug Saf; 2023 Jul; 32(7):783-794. PubMed ID: 36919526
[TBL] [Abstract][Full Text] [Related]
17. Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study.
Wan EYF; Chui CSL; Lai FTT; Chan EWY; Li X; Yan VKC; Gao L; Yu Q; Lam ICH; Chun RKC; Cowling BJ; Fong WC; Lau AYL; Mok VCT; Chan FLF; Lee CK; Chan LST; Lo D; Lau KK; Hung IFN; Leung GM; Wong ICK
Lancet Infect Dis; 2022 Jan; 22(1):64-72. PubMed ID: 34411532
[TBL] [Abstract][Full Text] [Related]
18. Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
Wong CKH; Lau KTK; Xiong X; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Chan EWY; Gao L; Cheng FWT; Tang SCW; Wong ICK
PLoS Med; 2022 Jun; 19(6):e1004018. PubMed ID: 35727759
[TBL] [Abstract][Full Text] [Related]
19. Transverse Myelitis Following SARS-CoV-2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database.
Nguyen S; Bastien E; Chretien B; Sassier M; Defer G; Nehme A; Lelong-Boulouard V; Alexandre J; Fedrizzi S; Morice PM
Ann Neurol; 2022 Dec; 92(6):1080-1089. PubMed ID: 36054163
[TBL] [Abstract][Full Text] [Related]
20. Sequential contralateral facial nerve palsies following COVID-19 vaccination first and second doses.
Burrows A; Bartholomew T; Rudd J; Walker D
BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34281950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
